NDC1基因在结肠癌中诊断及预后价值的生物信息学分析：一项基于TCGA数据库的研究

doi:10.3969/j.issn.1009-976X.2021.06.002

摘要/Abstract

摘要： 目的本研究旨在确定NDC1基因对结肠癌患者诊断和预后评估的作用。方法 NDC1基因的RNA-Seq数据以及对应的每一例患者的临床病理和预后参数从癌症基因图谱（TCGA）数据库下载,而后使用R软件绘制散点图并分析NDC1在结肠癌和癌旁正常组织中的差异化表达,绘制受试者曲（ROC）并分析NDC1基因表达对区分结肠癌患者和健康人的诊断效能。通过GEPIA数据库检索并绘制Kaplan-Meier曲线分析NDC1基因表达与结肠癌患者生存之间的关系,卡方检验分析NDC1基因表达和结肠癌患者临床病理特征的关系并采用单因素及多因素Cox回归模型分析影响结肠癌预后的因素。结果 NDC1表达量的中位数为3.797（3.411~4.118）,高于正常组织3.09（2.897~3.297）,差异有统计学意义（P<0.05）,并且在41对配对组织中的NDC1表达量同样高于对应的癌旁正常组织（P<0.05）,ROC曲线显示NDC1基因对结肠癌较高的诊断价值（AUC=0.8515,95%CI：0.8115~0.8915,P<0.001）。NDC1高表达的患者相比于低表达的患者有着更低的淋巴结转移数、更好的病理分期以及更少的肿瘤淋巴侵犯（P<0.05）。NDC1基因低表达的结肠癌患者有着更低的总体生存率（P<0.05）。单因素COX分析的结果显示患者的年龄、T分期、N分期、M分期、病理分期、淋巴侵犯以及NDC1基因的表达都是影响结肠癌患者的预后因素（P>0.05）。在多因素COX分析的结果显示年龄、M分期、病理分期是结肠癌患者预后的独立因素（P<0.05）。结论 NDC1基因有潜力成为一个用于结肠癌诊断及预后评估的新型生物学标志物。

关键词: NDC1, TCGA, 结肠癌, 预后

Abstract: Objective The aim of this study was to determine the role of the NDC1 gene in the diagnosis and prognostic assessment of patients with colon cancer. Methods RNA-Seq data of NDC1 gene and corresponding clinicopathological and prognostic parameters of each patient were downloaded from The Cancer Genome Atlas （TCGA） database, and R software was used to draw scatter plots and analyze the differential expression of NDC1 in tumor tissues and normal tissues, the receiver operating characteristic curve （ROC） was used to analyze the diagnostic efficacy of NDC1 gene expression in differentiating colon cancer patients from healthy individuals. The relationship between NDC1 gene expression and survival of colon cancer patients was analyzed by searching the Kaplan-Meier curves from GEPIA database. The relationship between NDC1 gene expression and clinicopathological characteristics of colon cancer patients was analyzed by chi-square test and the factors affecting the prognosis of colon cancer were analyzed by univariate and multifactorial Cox regression models. Results The median NDC1 expression was 3.797（3.411~4.118）, which was higher than that of normal tissues 3.09 （2.897~3.297） and the difference was statistically significant （P<0.05）, and the NDC1 expression in 41 paired tissues were also higher than that of the normal tissues adjacent to the tumor（P<0.05）. The ROC curve showed a higher diagnostic value of NDC1 gene for colon cancer （AUC=0.8515, 95% CI：0.8115~0.8915, P<0.001）. Patients with high NDC1 expression had lower number of lymph node metastases, better pathological stage and less lymphatic invasion compared with those with low NDC1 expression （P<0.05）. Colon cancer patients with low NDC1 gene expression had lower overall survival rates compared to those with high expression （P<0.05）. The results of univariate COX analysis showed that patients' age, T-stage, N-stage, M-stage, pathological stage, lymphatic invasion and NDC1 gene expression were all factors affecting the prognosis of patients with colon cancer （P>0.05）. The results of the multifactorial COX analysis showed that age, M stage, and pathological stage were independent factors in the prognosis of colon cancer patients （P<0.05）. Conclusion NDC1 gene has the potential to be a novel biological marker for the diagnosis and prognostic assessment of colon cancer

Key words: NDC1, TCGA, colon cancer, prognosis

中图分类号:

R735.3+5

胡明超, 朱宝松. NDC1基因在结肠癌中诊断及预后价值的生物信息学分析：一项基于TCGA数据库的研究[J]. 岭南现代临床外科, 2021, 21(06): 598-602.

HU Ming-chao, ZHU Bao-song. Bioinformatics analysis of the diagnostic and prognostic value of the NDC1 gene in colon cancer： a study based on TCGA database[J]. Lingnan Modern Clinics In Surgery, 2021, 21(06): 598-602.

参考文献

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2] Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2019, 5(12): 1749-1768.
[3] Tzeng CW, Aloia TA. Colorectal liver metastases [J]. J Gastrointest Surg, 2013, 17(1): 195-201; quiz p.201-202.
[4] Kemeny N.The management of resectable and unresectable liver metastases from colorectal cancer[J]. Curr Opin Oncol, 2010, 22(4): 364-73.
[5] Shen C, Hu L, Xia L, Li Y.Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients[J]. Jpn J Clin Oncol, 2008, 38(11): 770-776.
[6] Labianca R, Nordlinger B, Beretta GD, et al.Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up[J]. Ann Oncol, 2010, 21(suppl 5):v70-77.
[7] Duffy MJ, Lamerz R, Haglund C, et al.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update[J]. Int J Cancer, 2014, 134(11): 2513-2522.
[8] Zheng S, Cherniack AD, Dewal N, et al.Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma[J]. Cancer Cell, 2016, 30(2): 363.
[9] Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(7407): 330-337.
[10] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[11] Mattiuzzi C, Sanchis-Gomar F, Lippi G.Concise update on colorectal cancer epidemiology[J]. Ann Transl Med, 2019, 7(21): 609.
[12] Schmit K, Michiels C.TMEM Proteins in Cancer: A Review[J]. Front Pharmacol, 2018, 9:1345.
[13] Stavru F, Hülsmann BB, Spang A, et al.NDC1: a crucial membrane-integral nucleoporin of metazoan nuclear pore complexes[J]. J Cell Biol, 2006, 173(4): 509-519.
[14] D′Angelo, Angelo MA, Hetzer MW. Structure, dynamics and function of nuclear pore complexes[J]. Trends Cell Biol, 2008, 18(10): 456-466.
[15] Qiao W, Han Y, Jin W, et al.Overexpression and biological function of TMEM48 in non-small cell lung carcinoma[J]. Tumour Biol, 2016, 37(2): 2575-2586.
[16] Jiang XY, Wang L, Liu ZY, et al.TMEM48 promotes cell proliferation and invasion in cervical cancer via activation of the Wnt/β-catenin pathway[J]. J Recept Signal Transduct Res, 2021, 41(4): 371-377.